tetano
Editor, Senior Moderator
Vaccines (Basel)
. 2022 Sep 7;10(9):1494.
doi: 10.3390/vaccines10091494.
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
Ratchanon Sophonmanee[SUP] 1 [/SUP], Jomkwan Ongarj[SUP] 1 [/SUP], Bunya Seeyankem[SUP] 1 [/SUP], Purilap Seepathomnarong[SUP] 1 [/SUP], Porntip Intapiboon[SUP] 2 [/SUP], Smonrapat Surasombatpattana[SUP] 3 [/SUP], Supattra Uppanisakorn[SUP] 4 [/SUP], Pasuree Sangsupawanich[SUP] 4 [/SUP], Sarunyou Chusri[SUP] 2 [/SUP], Nawamin Pinpathomrat[SUP] 1 [/SUP]
Affiliations
Abstract
A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-CoV-2 vaccine. In this study, an intramuscular booster at full dosage was used as a control, and a half-dose vaccination was included for reciprocal comparison. Detailed T-cell studies are essential to understand cellular responses to vaccination. T-cell immunity was examined using S1 peptide restimulation and flow cytometry. The fractional dose (1:5) of the BNT162b2 mRNA vaccine enhanced antigen-specific effector T-cells, but the responses were less remarkable compared to the intramuscular booster at full dosage. However, the intradermal regimen was not inferior to the intramuscular booster a month after boosting. An intradermal booster using only one-fifth of the standard dosage could provide comparable T-cell responses with the fractional intramuscular booster. This work confirms the efficacy of intradermal and fractional vaccination in terms of T-cell immunogenicity in previously immunised populations.
Keywords: COVID-19; T-cells; inactivated SARS-CoV-2; intradermal; mRNA vaccine.
. 2022 Sep 7;10(9):1494.
doi: 10.3390/vaccines10091494.
T-Cell Responses Induced by an Intradermal BNT162b2 mRNA Vaccine Booster Following Primary Vaccination with Inactivated SARS-CoV-2 Vaccine
Ratchanon Sophonmanee[SUP] 1 [/SUP], Jomkwan Ongarj[SUP] 1 [/SUP], Bunya Seeyankem[SUP] 1 [/SUP], Purilap Seepathomnarong[SUP] 1 [/SUP], Porntip Intapiboon[SUP] 2 [/SUP], Smonrapat Surasombatpattana[SUP] 3 [/SUP], Supattra Uppanisakorn[SUP] 4 [/SUP], Pasuree Sangsupawanich[SUP] 4 [/SUP], Sarunyou Chusri[SUP] 2 [/SUP], Nawamin Pinpathomrat[SUP] 1 [/SUP]
Affiliations
- PMID: 36146571
- DOI: 10.3390/vaccines10091494
Abstract
A practical booster vaccine is urgently needed to control the coronavirus disease (COVID-19) pandemic. We have previously reported the safety and immunogenicity of a fractional intradermal booster, using the BNT162b2 mRNA vaccine in healthy volunteers who had completed two doses of inactivated SARS-CoV-2 vaccine. In this study, an intramuscular booster at full dosage was used as a control, and a half-dose vaccination was included for reciprocal comparison. Detailed T-cell studies are essential to understand cellular responses to vaccination. T-cell immunity was examined using S1 peptide restimulation and flow cytometry. The fractional dose (1:5) of the BNT162b2 mRNA vaccine enhanced antigen-specific effector T-cells, but the responses were less remarkable compared to the intramuscular booster at full dosage. However, the intradermal regimen was not inferior to the intramuscular booster a month after boosting. An intradermal booster using only one-fifth of the standard dosage could provide comparable T-cell responses with the fractional intramuscular booster. This work confirms the efficacy of intradermal and fractional vaccination in terms of T-cell immunogenicity in previously immunised populations.
Keywords: COVID-19; T-cells; inactivated SARS-CoV-2; intradermal; mRNA vaccine.